ROSEN, GLOBAL INVESTOR COUNSEL, encourages TG Therapeutics, Inc. investors with losses to secure… | Your money

NEW YORK, Sept. 03, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds buyers of TG Therapeutics, Inc. (NASDAQ: TGTX) securities between the January 15, 2020 and May September 31, 2022, both inclusive dates (the “Class Period”), of the important deadline of September 16, 2022 for lead plaintiff.

SUCH AS: If you purchased securities of TG Therapeutics during the Class Period, you may be entitled to compensation without payment of fees or out-of-pocket costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the TG Therapeutics class action lawsuit, go to https://rosenlegal.com/submit-form/?case—id=7662 or call Phillip Kim, Esq. toll free at 866-767-3653 or by email [email protected] Where [email protected] for more information on the class action. A class action lawsuit has already been filed. If you wish to act as a lead plaintiff, you must move the Court no later than September 16, 2022. A lead plaintiff is a representative party acting on behalf of other class members to direct litigation.

WHY ROSEN LAW: We encourage investors to select qualified lawyers with proven track records in leadership roles. Often, companies issuing reviews do not have comparable experience, resources, or significant peer recognition. Many of these firms do not actually handle securities class action lawsuits, but are merely middlemen who refer clients or partner with law firms that actually litigate the cases. Be wise in choosing lawyers. Rosen Law Firm represents investors worldwide, focusing its practice on securities class action and shareholder derivative litigation. Rosen Law Firm has reached the largest securities class action settlement against a Chinese company. Rosen Law Firm was ranked #1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017. The firm has ranked in the top 4 every year since 2013 and has recovered hundreds of million dollars for investors. In 2019 alone, the company secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s lawyers have been recognized by Lawdragon and Super Lawyers.

CASE DETAILS: According to the lawsuit, throughout the Class Period, the Defendants made false and/or misleading statements and/or failed to disclose that: (1) clinical trials revealed significant concerns related to the benefit/risk ratio and overall survival data of Ublituximab (an investigational glycoengineered monoclonal antibody for the treatment of non-Hodgkin’s B-cell lymphoma, chronic lymphocytic leukemia (“CLL”) and relapsing forms of multiple sclerosis) and Umbralisib (or UKONIQ, an oral PI3K-delta and CK1-epsilon inhibitor for the treatment of CLL, marginal zone lymphoma and follicular lymphoma); (2) therefore, it was unlikely that TG Therapeutics would be able to obtain U.S. Food and Drug Administration (“FDA”) approval for marginal zone lymphoma (“MZL”) and Follicular Lymphoma (“FL”) (the “Umbralisib MZL/FL NDA”), the ongoing submission of a Biologics License Application (“BLA”) to the FDA for Ublituximab in combination with Umbralisib ( together, “U2”), as a treatment for patients with CLL (the “U2 BLA”), the Supplemental New Drug Application (“sNDA”) for Umbralisib to add an indication for CLL and small lymphocytic lymphoma (“SLL”) in combination with Ublituximab (the “U2 sNDA”), or Ublituximab as a treatment for patients with relapsing forms of multiple sclerosis (“RMS”) (the “Ublituximab RMS BLA”) in their current forms; (3) as a result, TG Therapeutics had significantly overestimated the clinical and/or commercial prospects of Ublituximab and Umbralisib; and (4) therefore, the Company’s public statements were materially false and misleading at all relevant times. When the real details entered the market, the lawsuit claims investors suffered damages.

To join the TG Therapeutics class action lawsuit, go to https://rosenlegal.com/submit-form/?case—id=7662 or call Phillip Kim, Esq. toll free at 866-767-3653 or by email [email protected] Where [email protected] for more information on the class action.

No class has been certified. Until a class is certified, you are not represented by an attorney unless you retain one. You can choose the lawyer of your choice. You can also remain an absent party member and do nothing at this point. An investor’s ability to participate in any potential future recovery does not depend on their status as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firmon Twitter: https://twitter.com/rosen—company or on Facebook: https://www.facebook.com/rosenlawfirm/.

Lawyer advertisement. Previous results do not guarantee a similar result.

——————————-

Contact information:

Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, PA 275 Madison Avenue, 40th Floor New York, NY 10016 Tel. Toll Free: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com

Copyright 2022 GlobeNewswire, Inc.

Comments are closed.